A recent publication by CliCr inventor Matt Timmers describes an engineered SpCas9 platform bearing azide handles, enabling site-specific CliCr conjugation of siRNA while preserving both Cas9 editing and siRNA silencing activity. By applying the same CliCr chemistry, researchers can also generate targeted Cas9–siRNA–loaded LNPs, demonstrating a route to highly programmable and optimized delivery of gene-editing […]

Paterna, Valencia, SPAIN and Maastricht, THE NETHERLANDS – 26 November 2025, Curapath, a leading innovator in the development and manufacturing of polymer and lipid-based drug delivery systems, and Cristal Therapeutics, a biotech company developing innovative conjugation technologies, today announced they entered into a co-exclusive license agreement for the CliCr® bioconjugation platform. The platform offers a […]

Maastricht, The Netherlands – 11 September 2025 Cristal Therapeutics, a biotech company developing innovative conjugation technologies, today announced it has entered into a non-exclusive license agreement with Sapreme Technologies. The agreement allows Sapreme Technologies to leverage the versatile and highly efficient CliCr® platform in the development of next-generation therapeutics based on their endosomal escape technology. […]

20230117 Lonza collaborates with Cristal Therapeutics “CliCr® is a powerful metal-free click chemistry technology for the life science industry which offers shorter reaction times and greater yields and hence attractive CoG than comparative reagents on the market. Our collaboration with Lonza will help to extend the impact of this innovative technology for use in straightforward […]